BRIEF-Arch Biopartners Receives Health Canada Authorization To Amend Phase Ii Trial Protocol For Lsalt Peptide

Reuters · 03/16/2021 12:57
BRIEF-Arch Biopartners Receives Health Canada Authorization To Amend Phase Ii Trial Protocol For Lsalt Peptide

- Arch Biopartners Inc ARCH.V:

  • ARCH BIOPARTNERS RECEIVES HEALTH CANADA AUTHORIZATION TO AMEND PHASE II TRIAL PROTOCOL FOR LSALT PEPTIDE

Source text for Eikon: ID:nGNX5nldkk

Further company coverage: ARCH.V


((Reuters.Briefs@thomsonreuters.com;))